The IVIS® Lumina™ S5 high-throughput 2D optical imaging system combines high-sensitivity bioluminescence and fluorescence in a benchtop format. With an expanded 5 mouse field of view for 2D optical imaging plus our unique line of accessories to accelerate setup and labeling, it has never been easier or faster to get robust data—and answers—on anatomical and molecular aspects of disease.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The IVIS Lumina S5 in vivo imaging system has all the capabilities of the current IVIS Lumina platform with improved throughput and accessories to streamline imaging workflow, data acquisition and analysis, ideal for accelerating your research.
High-throughput High-Sensitivity Optical Imaging
The IVIS Lumina S5 integrates a 1 inch CCD camera into our benchtop instrument providing a high throughput 20 x 20 cm Field of View (FOV) sufficient for imaging 5 animals at a time for bioluminescence and fluorescence in vivo imaging.
As with other IVIS Lumina in vivo optical imaging systems, the S5 is equipped with 26 filters tunable to image fluorescent sources that emit from green to near-infrared. Novel illumination technology effectively increases fluorescent transmission through 900 nm. Moreover, the IVIS Lumina S5 incorporate PerkinElmer's patented Compute Pure Spectrum (CPS) algorithm for spectral library generation software tools to ensure accurate autofluorescence removal, unmixing and fluorophore quantitation. Standard on all IVIS instruments, absolute calibration affords consistent and reproducible results independent of magnification, filter selection from one instrument to any another IVIS instrument within an organization or around the world.
Not only does the IVIS Lumina S5 offer higher throughput via the 1 inch CCD, but it is also compatible with a set of smart animal handling accessories (purchased separately) designed with throughput and safety in mind.
Smart loading trays will allow users to pose animals on the benchtop before placing the tray into the IVIS. Fiducials built into the tray will allow the software to automatically recognize and draw ROIs providing automated animal identification.
Animal trays are designed with ease of use and user safety in mind. No nose cones are required thus minimizing cleanup. All tray parts are autoclaveable for ease of sterilization and when used with the next generation anesthesia unit (RAS-4), strong vacuum capabilities minimize excess gas from escaping thus preventing exposure of users to anesthetic gas.
Finally, Living Image® software brings IVIS technology to life by facilitating an intuitive workflow for in vivo optical image acquisition, analysis and data organization. The software’s design creates an intuitive, seamless workflow for researchers of all skill levels. Living Image will support input of unique animal IDs when using chip technologies and readers from third party vendors thus streamlining labeling , setup and subsequent export of data for analysis.
For additional publications, please visit Google Scholar.
|Imaging Modality||Optical Imaging|
|Product Brand Name||IVIS|
Aside from the traditional small-molecule chemotherapeutics or targeted therapy agents that have been widely used in the clinic for decades, a new type of cancer therapeutics based on oncolytic viruses has recently gained attention in the field of research. Oncolytic viruses are genetically modified viruses capable of delivering therapeutic gene payload to cancer cells.
There are many types of oncolytic viruses each having a different tumor-targeting mechanism. This application note highlights using Sindbis pseudovirus genetically modified with firefly luciferase reporter gene to non-invasively evaluate, monitor, and quantify oncolytic viral infection in living tumors and subsequent virus-host interactions in real-time using IVIS® optical imaging.
Gene therapy is a very powerful tool that is currently being explored to combat disorders with underlying genetic causes. Within the field of neurological diseases, there is great interest looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs (rAAVs), scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Amyotrophic lateral sclerosis (ALS) is a devastating neurological disease for which there is no cure. Another lethal brain disease is stroke, which occurs when blood supply to the brain is disrupted by a blood vessel that bursts or becomes blocked. Neuroinflammation plays a key role in both of these diseases as well as in the pathogenesis for Alzheimer’s, multiple sclerosis, and other forms of brain injury.
Read this case study where Dr. Jasna Kriz and her colleagues at Laval University in Quebec, developed transgenic mouse models for optical imaging of cells such as astroglia, microglia, and neurons. Mice were modified to express firefly luciferase when immune processes are activated enabling the researchers to study early neuroinflammatory events using the high sensitivity 2D & 3D optical imaging on the IVIS® platform.
CAR T therapy has achieved tremendous success in treating blood malignancies, however treating solid tumors with this therapy has proven to be challenging due to several factors such as on-tumor, off-tumor toxicity.
Read this case study where researchers from University of Pennsylvania created a mouse model that expresses tumor associated antigens in normal tissue to study off-tumor CART-T cell toxicity. These studies used optical imaging on the IVIS® platform to longitudinally monitor off-tumor antigen expression, tumor progression, and CAR-T cell trafficking in live animals.
Obesity is a global epidemic that is the fifth leading cause of death worldwide and in the US alone, nearly 85% of adults are expected to be overweight or obese by 2030. In addition to the increased risk of overall mortality, obesity is associated with an increased risk for other metabolic disorders such as diabetes and heart disease which pose a significant burden to health care systems.
Read this case study to learn how researchers at the Joslin Diabetes Center in Boston, Massachusetts used the IVIS® optical imaging system to visualize and quantify CRISPR/Cas9 engineered adipose tissue in a mouse model to study the prevention of obesity and obesity-related metabolic disorders.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Influenza is a highly infectious airborne disease with an important societal burden. Annual epidemics have occurred throughout history causing tens of millions of deaths. Even a run-of-the-mill influenza infection can be debilitating to otherwise healthy people, and lethal to those who are elderly or frail, so vaccinations are important. Because of seasonal antigenic drift and antiviral resistance of the virus there is a critical need for the development of new and novel vaccines and antiviral drugs. In vivo optical imaging has emerged as a powerful, non-invasive tool to track viral load and therapeutic efficacy of vaccines and immunotherapies in small animal models.
Read how researchers at the NIH, NIAID, Emory University, and University of Wisconsin used the IVIS® optical imaging platform to successfully quantify and track viral load in mice and demonstrated that vaccine of human mAb administration has a protective or therapeutic effect in mice challenged with the influenza virus.
A large percentage of Type 2 diabetes mortality is related to cardiovascular complications. Consequently, there is a critical need for creating novel therapeutics that not only manage blood glucose levels, but also reduce the risk of developing cardiovascular diseases.
Liraglutide (Lira) is a recently approved drug used to treat Type II diabetes with excellent hypoglycemic effects while also improving cardiovascular function in patients. However its short half-life requires daily injections increasing the risk of poor patient compliance and other complications.
Read this publication review to learn how researchers used a Type II diabetes mouse model and optical imaging with the IVIS® platform to evaluate a nanoparticle system that offers a sustained and controlled release of Lira that overcomes the challenges of the short half-life of the drug.
Viral diseases have emerged and re-emerged throughout history, and as the human population continues to increase globally, so will the frequency of viral pandemics. Not only have Ebola and COVID-19 demonstrated most recently mankind’s vulnerability to contagious diseases, but also the challenges we are faced with from a therapeutic standpoint.Read how non-invasive optical imaging enables the most intricate host-pathogen interactions to be visualized and monitored in disease models that mimic what is seen in humans. Not only does optical imaging play an important role in better understanding the complex mechanisms of viral biology, it plays a vital role in the discovery and development of new drug and vaccine candidates.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.